Chidamide, Rituximab Plus EAC Regimen with Autologous Hemopoietic Stem Cell Transplantation in High-risk and Relapsed/Refractory B-cell Lymphoma and Long Term Follow-up
本文未提供摘要,请点击“查看全文”查看完整内容。